Stephen A. Tullman, Director at Aclaris Therapeutics, Inc. (ACRS), bought 12,500 shares at $15.97 ($200K) on 2018-08-15, disclosed to the SEC on 2018-08-17.
Open-market purchase of $200k ACRS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.97 | 6,250 | $100K | 50.0% |
| 2 | $15.97 | 6,250 | $100K | 50.0% |
| Total | $15.97 avg | 12,500 | $200K | 100% |
| Filing → |
| ACRS | BUY | 2018-04-09 | $442K | — | Filing → |